Brad Middlekauff

Before joining Immunovant, W. Bradford Middlekauff most recently served as Senior Vice President, General Counsel and Secretary at PDS Biotechnology Corporation (formerly known as Edge Therapeutics), where he was responsible for all legal and compliance aspects of a publicly traded life science company. He previously served as Chief Legal Officer, General Counsel and Secretary at Kolltan Pharmaceuticals, where he also ran the business development function; Senior Vice President, General Counsel and Secretary of Medarex, a publicly traded antibody company that developed the products later known as Yervoy® and Opdivo® and was sold to Bristol-Myers Squibb for $2.4 billion; and Vice President, Business Development and General Counsel at Algos Pharmaceuticals, a publicly traded drug development company that was sold to Endo Pharmaceuticals. Mr. Middlekauff served on the Executive Committee at each of these companies. He has served as Executive-in-Residence at Princeton University and is a member of the board of directors of ProteoDesign, a biotechnology company based in Barcelona, Spain.